Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Debt: 2019-2024

Historic Total Debt for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $8.4 million.

  • Beam Therapeutics' Total Debt fell 22.62% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $8.4 million for FY2024, which is 22.22% down from last year.
  • As of FY2024, Beam Therapeutics' Total Debt stood at $8.4 million, which was down 22.22% from $10.8 million recorded in FY2023.
  • Beam Therapeutics' Total Debt's 5-year high stood at $71.2 million during FY2020, with a 5-year trough of $8.4 million in FY2024.
  • In the last 3 years, Beam Therapeutics' Total Debt had a median value of $10.8 million in 2023 and averaged $12.5 million.
  • As far as peak fluctuations go, Beam Therapeutics' Total Debt skyrocketed by 812.82% in 2020, and later plummeted by 56.64% in 2022.
  • Beam Therapeutics' Total Debt (Yearly) stood at $71.2 million in 2020, then tumbled by 40.73% to $42.2 million in 2021, then slumped by 56.64% to $18.3 million in 2022, then plummeted by 40.98% to $10.8 million in 2023, then fell by 22.22% to $8.4 million in 2024.